Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Fiasp® (insulin aspart) – Expanded indication
December 19, 2019 - The FDA approved Novo Nordisk’s Fiasp (insulin aspart), to improve glycemic control in adult and pediatric patients with diabetes mellitus.
